Drug · CHEMBL580

LORAZEPAM

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. LORAZEPAM. Drugs and targets, record CHEMBL580. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL580

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: LORAZEPAM; ChEMBL
ChEMBL ID: CHEMBL580; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Abbloraz, Ativan, Loraz, Lorazepam intensol, Lorazepam preservative free, Loreev xr, Temesta; ChEMBL
Other names: Lorazepam civ, NSC-289758, WY-4036; ChEMBL
DrugBank: DB00186; DrugBank
InChIKey: DIWRORZWFLOCLC-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 28 diseases, from ATC, DailyMed, PMDA and TTD; Open Targets

Targets16

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
GABRA1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2554
GABRA2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2555
GABRA3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2556
GABRA4	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2557
GABRA5	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2558
GABRA6	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2559
GABRB1	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2560
GABRB2	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2561
GABRB3	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2562
GABRD	GABA-A receptor; anion channel	GABA-A receptor; anion channel positive allosteric modulator	POSITIVE ALLOSTERIC MODULATOR	https://conductscience.org/library/genes/2563

1 to 10 of 16Source ChEMBL

See all 16 targets

Diseases28

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
status epilepticus	Approval	DailyMed and PMDA	11	9	https://conductscience.org/library/drugs?q=EFO_0008526
generalized anxiety disorder	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0001942
major depressive disorder	Approval	DailyMed	106	2	https://conductscience.org/library/drugs?q=MONDO_0002009
anxiety	Approval	ATC	4	2	https://conductscience.org/library/drugs?q=MONDO_0011918
Agitation	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0000713
Pain	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0012531
Seizure	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0001250
alcohol withdrawal	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005433
bipolar disorder	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004985
convulsion	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_0009853

1 to 10 of 28Source Open Targets

See all 28 diseases

Trials105

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00809146	Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications	Phase 3	1,023	2012-04-13	lorazepam	Its name	ClinicalTrials.gov
NCT00624780	Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder	Phase 4	615	2013-04-19	lorazepam	Its name	ClinicalTrials.gov
NCT02305797	EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)	Phase 3	495	2018-09-26	lorazepam	Its name	ClinicalTrials.gov
NCT01441843	Resistance Under the Microscope	Phase 4	400	2014-03-10	lorazepam	Its name	ClinicalTrials.gov
NCT00807937	Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325	Phase 2	369	2010-10-08	lorazepam	Its name	ClinicalTrials.gov
NCT01949662	Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer	Phase 2	93	2020-10-30	lorazepam	Its name	ClinicalTrials.gov
NCT03331042	SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.	Phase 3	85	2019-06-05	lorazepam	Its name	ClinicalTrials.gov
NCT00457366	A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room	Phase 4	72	2019-07-05	lorazepam	Its name	ClinicalTrials.gov
NCT00797277	Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia	Phase 3	67	2014-09-15	lorazepam	Its name	ClinicalTrials.gov
NCT01889602	Characterizing and Predicting Drug Effects on Cognition	Phase 4	60	2019-12-17	lorazepam	Its name	ClinicalTrials.gov

1 to 10 of 105

See all 105 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
IM Midazolam vs IV Lorazepam: serious adverse events	137 of 514	156 of 509	1,023	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Admitted to an Intensive Care Unit (ICU)	128 of 448	161 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival	51 of 448	47 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival	63 of 448	64 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given	329 of 448	282 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With Hypotension	12 of 448	13 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects Hospitalized	258 of 448	292 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IM Injection-site Complications	4 of 448	2 of 445	893	NCT00809146	Trial comparisons
IM Midazolam vs IV Lorazepam: Number of Subjects With IV Injection-site Complications	0 of 448	3 of 445	893	NCT00809146	Trial comparisons
EDG004 vs Placebo: serious adverse events	2 of 247	0 of 248	495	NCT02305797	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials54

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38186562	RESULT	1	PubMed
36448276	RESULT	1	PubMed
35971024	RESULT	1	PubMed
34820831	RESULT	1	PubMed
34546899	RESULT	1	PubMed
34238838	RESULT	1	PubMed
33728561	RESULT	1	PubMed
33692709	RESULT	1	PubMed
32029262	RESULT	1	PubMed
28781452	RESULT	1	PubMed

1 to 10 of 54

See all 54 papers from its trials

Tests in its trials16

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Verbal Learning	4	1	ConductCognition
Symbol Coding	3	0	ConductCognition
Hidden Path Learning	2	2	ConductCognition
Choice Reaction Time	1	0	ConductCognition
Delayed Recall Module	1	0	ConductCognition
Digit Span Test	1	0	ConductCognition
1-Back Task	1	0	ConductCognition
2-Back Task	1	0	ConductCognition
Paired Associate Learning	1	0	ConductCognition
Simple Reaction Time	1	0	ConductCognition

1 to 10 of 16

See all 16 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL580

GET https://conductscience.org/api/drugs/v1/CHEMBL580/diseases?page=2

API reference For AI assistants